Benzinga · Mar 3, 2026
SO
NASDAQ · SOPH
SOPHiA GENETICS S.A.
Healthcare · Medical - Healthcare Information Services
$8.19
Down-$0.34 (-3.99%)
Updated Sep 20, 2026, 3:06 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 321.51M
- P/E ratio
- -4.39
- Dividend yield
- 0.00%
- 52-week range
- $4.28 – $8.98
- Volume
- 965.13K
- Avg. volume
- 114.15K
Price performance
SOPH price history
1M range · 19 trading sessions · Daily adjusted prices
SOPH closed at $8.19 after 19 trading sessions, down 3.08% for the selected period.
- Last close
- $8.19
- Period change
- -3.08%
- Period low
- $7.61
- Period high
- $8.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $8.55 | $8.70 | $8.12 | $8.19 | 965.13K |
| Sep 17, 2026 | $8.10 | $8.60 | $8.06 | $8.53 | 1.21M |
| Sep 16, 2026 | $7.98 | $8.10 | $7.8305 | $7.975 | 1.49M |
| Sep 15, 2026 | $7.85 | $7.98 | $7.76 | $7.96 | 1.86M |
| Sep 14, 2026 | $7.87 | $8.00 | $7.755 | $7.86 | 309.53K |
| Sep 11, 2026 | $7.64 | $7.88 | $7.53 | $7.87 | 243.55K |
| Sep 10, 2026 | $7.66 | $7.8099 | $7.535 | $7.61 | 378.55K |
| Sep 9, 2026 | $8.37 | $8.37 | $7.64 | $7.68 | 799.47K |
| Sep 8, 2026 | $7.99 | $8.39 | $7.86 | $8.36 | 461.98K |
| Sep 4, 2026 | $8.24 | $8.30 | $8.0625 | $8.09 | 147.03K |
| Sep 3, 2026 | $8.30 | $8.36 | $7.93 | $8.30 | 698.27K |
| Sep 2, 2026 | $8.47 | $8.62 | $7.82 | $8.28 | 809.62K |
| Sep 1, 2026 | $8.30 | $8.48 | $8.13 | $8.425 | 766.05K |
| Aug 31, 2026 | $8.09 | $8.4902 | $8.03 | $8.40 | 748.95K |
| Aug 28, 2026 | $8.80 | $8.91 | $8.06 | $8.14 | 417.17K |
| Aug 27, 2026 | $8.55 | $8.98 | $8.44 | $8.92 | 614.24K |
| Aug 26, 2026 | $8.58 | $8.62 | $8.31 | $8.53 | 232.06K |
| Aug 25, 2026 | $8.45 | $8.85 | $8.32 | $8.65 | 798.63K |
| Aug 24, 2026 | $8.63 | $8.84 | $8.36 | $8.45 | 655.65K |
Latest SOPH news
The latest Smart Investors Daily articles mentioning SOPH.
Stock researchCompany · Overview
SOPH research
Overview
Company profile and research snapshot.
Company profile
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.33
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2026 | BTIG | Buy | — |
| May 6, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
ChartMill · Mar 3, 2026
SOPHiA GENETICS SA (NASDAQ:SOPH) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss
SOPHiA GENETICS reports Q4 2025 revenue beat but wider-than-expected loss, highlighting growth in AI-driven genomic analysis as path to profitability continues.
SeekingAlpha · Mar 3, 2026
SOPHiA GENETICS SA 2025 Q4 - Results - Earnings Call Presentation
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
